These results may help in a better understanding of the effects of KRAS mutations in not only NSCLC but also other types of cancers such as colorectal cancer where KRAS mutational status is a major determinant in the selection of optimal therapeutic regimes for individual patients. Here, KRAS is linked to non-small cell lung carcinoma.